<DOC>
	<DOCNO>NCT00002026</DOCNO>
	<brief_summary>To evaluate efficacy oral acyclovir treatment suppression Epstein-Barr virus ( EBV ) relate hairy leukoplakia ( HL ) . To determine long-term safety acyclovir AIDS-related complex ( ARC ) patient HL . To monitor progression HIV disease HL patient compare exist historical control data .</brief_summary>
	<brief_title>Treatment Suppression Hairy Leukoplakia ARC Patients With Oral Acyclovir ( ACV )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<mesh_term>Leukoplakia , Hairy</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical antifungal therapy . Patient must : Newly diagnose clinical histological hairy leukoplakia . Positive HIV antibody license ELISA Western blot . Exclusion Criteria Coexisting Condition : Patients AIDS history intolerance allergy acyclovir exclude . Concurrent Medication : Excluded within 2 week study entry : Systemic antifungal treatment . Excluded within 6 week study entry : Immunomodulators . Systemic antiviral treatment . Patients AIDS history intolerance allergy acyclovir exclude . Prior Medication : Excluded within 2 week study entry : Systemic antifungal . Excluded within 6 week study entry : Immunomodulators . Systemic antiviral treatment . Excluded within 8 week study entry : Zidovudine ( AZT ) antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Leukoplakia , Oral</keyword>
	<keyword>Herpesvirus 4 , Human</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>